Related Experiment Video

Updated: May 9, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Treatment with novel oral anticoagulants: indications, efficacy and risks

Shari Ghanny1, Mark Crowther

  • 1Department of Medicine, McMaster University, Hamilton, Ontario, Canada.

Current Opinion in Hematology
|July 16, 2013
PubMed
Abstract

Insights

Novel oral anticoagulants (nOACs) are effective alternatives to vitamin K antagonists (VKAs) for preventing stroke and venous thromboembolism (VTE). While generally safe, careful patient selection is crucial, especially for those with renal issues or on other antithrombotics.

Area of Science:

  • Cardiology
  • Pharmacology
  • Hematology

Background:

  • Vitamin K antagonists (VKAs) have been traditional anticoagulants.
  • Novel oral anticoagulants (nOACs) offer potential alternatives.
  • Key nOACs include apixaban, dabigatran, and rivaroxaban.

Purpose of the Study:

  • To review data on nOACs as alternatives to VKAs.
  • To summarize efficacy and safety of nOACs in major indications.

Main Methods:

  • Review of pivotal clinical trials comparing nOACs with warfarin.
  • Focus on studies in atrial fibrillation and venous thromboembolism (VTE).

Main Results:

  • nOACs demonstrated non-inferiority to warfarin for stroke prevention in atrial fibrillation.
  • nOACs showed comparable efficacy to warfarin in acute and extended VTE treatment.
  • nOACs exhibited a favorable bleeding profile compared to warfarin, particularly regarding fatal and major bleeding.

Conclusions:

  • nOACs are effective and safe alternatives to VKAs for stroke prevention in atrial fibrillation and VTE treatment.
  • Careful consideration of patient-specific factors is necessary for optimal nOAC use.
  • Special populations requiring attention include those with renal insufficiency, on concomitant antithrombotic therapy, or with high bleeding risk.

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...